Analysts await Auris Medical Holding AG (NASDAQ:EARS) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.29 EPS, down 41.38% or $0.12 from last year’s $-0.17 per share.

At the moment 4 analysts are watching Auris Medical Holding AG (NASDAQ:EARS), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 0.00 million.

In terms of earnings per share, 1 analyst has a -0.29 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.33 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -1.09 EPS.

The biggest institutional shareholders in Auris Medical Holding AG include Wasatch Advisors Inc. which owns 3 million shares in the company valued at $13.65 million. Bellevue Asset Management AG is the second biggest holder with 2 million shares currently valued at 9.24 million whilst Fidelity Management and Research Company has 2 million shares valued at 7.10 million.

Total shares held by institutions as of the most recent company filings are 11,511,276 with a reported 33,826 bought and 598,683 sold. These holdings make up 40.11% of the company’s outstanding shares.

The stock increased 2.50% or $0.11 during the last trading session, hitting $5.25. Auris Medical Holding AG (NASDAQ:EARS) has risen 9.9% over the past 6 months and is uptrending.